RxDoctor Payments Data

Dhinesh Samuel, MD

Internal Medicine · Butler, PANPI 1164492831

Payments from drug & device makers

$7,596in general payments, 2019–2025

Across 480 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$926
  • Grifols USA, LLC$777
  • Pfizer$682
  • Lilly USA, LLC$455
  • GSK$444
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,569100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,596 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$70,349
Medicare patients
208
Services billed
654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban363$262,997
JardianceEmpagliflozin105$97,961
XareltoRivaroxaban109$86,014
TrulicityDulaglutide62$71,861
OzempicSemaglutide68$71,314
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$32,959
MyrbetriqMirabegron56$32,255
RexultiBrexpiprazole20$25,548
EntrestoSacubitril/Valsartan28$23,700
Breo ElliptaFluticasone/Vilanterol47$21,612
ProliaDenosumab11$19,169
Repatha SureclickEvolocumab16$12,208
EdecrinEthacrynic Acid14$12,191
JanumetSitagliptin Phos/Metformin Hcl17$9,793
Mirabegron ErMirabegron23$8,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$682$262,997363 claims
Boehringer IngelheimJardiance$321$97,961105 claims
Johnson & JohnsonXarelto$319$86,014109 claims
Lilly USA, LLCTrulicity$455$71,86162 claims
Novo NordiskOzempic$1,205$71,31468 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$444$61,43094 claims
Astellas Pharma US IncMyrbetriq$90$32,25556 claims
Otsuka America Pharmaceutical, Inc.Rexulti$52$25,54820 claims
NovartisEntresto$96$23,70028 claims
AmgenProlia$199$19,16911 claims
MerckJanumet$201$9,79317 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$44$7,70816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →